Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting β2-agonist, in patients with mild asthma

Journal of Allergy and Clinical Immunology

Volumn 124, Issue 6, 2009, Pages 1217-1221

  O'Byrne, Paul M ^a   van der Linde, Just ^a   Cockcroft, Donald W ^c   Gauvreau, Gail M ^a   Brannan, John D ^a   FitzGerald, Mark ^d   Watson, Richard M ^a   Milot, Joanne ^b   Davis, Beth ^c   O'Connor, Megan ^a   Hart, Lorna ^e   Korducki, Lawrence ^e   Hamilton, Alan L ^e   Boulet, Louis Philippe ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

Asthma; bronchodilators; functional antagonists; long acting inhaled 2 agonists; methacholine

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BI 1744; LONG ACTING DRUG; METHACHOLINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INFLUENZA; MALE; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHACHOLINE CHLORIDE; RECEPTORS, ADRENERGIC, BETA-2;

EID: 71149097092     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.08.047     Document Type: Article

References (28)

1. Bateman E.D., Hurd S.S., Barnes P.J., Bousquet J., Drazen J.M., Fitzgerald M., et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31 (2008) 143-178
2. Anderson S.D. Drugs and the control of exercise-induced asthma. Eur Respir J 6 (1993) 1090-1092
3. O'Byrne P.M., Morris M., Roberts R., and Hargreave F.E. Inhibition of the bronchial response to respiratory heat exchange by increasing doses of terbutaline sulphate. Thorax 37 (1982) 913-917
4. Pauwels R.A., Lofdahl C.G., Postma D.S., Tattersfield A.E., O'Byrne P., Barnes P.J., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337 (1997) 1405-1411
5. O'Byrne P.M., Bisgaard H., Godard P.P., Pistolesi M., Palmqvist M., Zhu Y., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171 (2005) 129-136
6. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J., Pauwels R.A., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170 (2004) 836-844
7. Anderson G.P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci 52 (1993) 2145-2160
8. Ball D.I., Brittain R.T., Coleman R.A., Denyer L.H., Jack D., Johnson M., et al. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol 104 (1991) 665-671
9. Celli B.R., Thomas N.E., Anderson J.A., Ferguson G.T., Jenkins C.R., Jones P.W., et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178 (2008) 332-338
10. Hargreave F.E., Ryan G., Thomson N.C., O'Byrne P.M., Latimer K., Juniper E.F., et al. Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance. J Allergy Clin Immunol 68 (1981) 347-355
11. Ramsdale E.H., Otis J., Kline P.A., Gontovnick L.S., Hargreave F.E., and O'Byrne P.M. Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formoterol. Am Rev Respir Dis 143 5 pt 1 (1991) 998-1001
12. Morris J.F., Koski A., and Johnson L.C. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis 103 (1971) 57-67
13. Newman S.P., Brown J., Steed K.P., Reader S.J., and Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest 113 (1998) 957-963
14. Standardization of spirometry. 1994 update. American Thoracic Society. Am J Respir Crit Care Med 152 (1995) 1107-1136
15. Cockcroft D.W., Killian D.N., Mellon J.J., and Hargreave F.E. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 7 (1977) 235-243
16. Inman M.D., Hamilton A.L., Kerstjens H.A., Watson R.M., and O'Byrne P.M. The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs. J Allergy Clin Immunol 101 (1998) 342-348
17. Derom E.Y., Pauwels R.A., and Van der Straeten M.E. The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours. J Allergy Clin Immunol 89 (1992) 811-815
18. Rabe K.F., Jorres R., Nowak D., Behr N., and Magnussen H. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 147 6 pt 1 (1993) 1436-1441
19. Ahrens R.C., Harris J.B., Milavetz G., Annis L., and Ries R. Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma. J Allergy Clin Immunol 79 (1987) 876-882
20. Orgel H.A., Kemp J.P., Tinkelman D.G., and Webb Jr. D.R. Bitolterol and albuterol metered-dose aerosols: comparison of two long-acting beta 2-adrenergic bronchodilators for treatment of asthma. J Allergy Clin Immunol 75 1 pt 1 (1985) 55-62
21. de Vries K., Goei J.T., Booy-Noord H., and Orie N.G.M. Changes during 24 hours in the lung function and histamine hyperreactivity of the bronchial tree in asthmatic and bronchitic patients. Int Arch Allergy 20 (1962) 93-101
22. Manning P.J., Jones G.L., and O'Byrne P.M. Tachyphylaxis to inhaled histamine in asthmatic subjects. J Appl Physiol 63 (1987) 1572-1577
23. Stevens W.H., Manning P.J., Watson R.M., and O'Byrne P.M. Tachyphylaxis to inhaled methacholine in normal but not asthmatic subjects. J Appl Physiol 69 (1990) 875-879
24. Simons F.E., Gerstner T.V., and Cheang M.S. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 99 (1997) 655-659
25. Bhagat R., Kalra S., Swystun V.A., and Cockcroft D.W. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 108 (1995) 1235-1239
26. Bhagat R., Swystun V.A., and Cockcroft D.W. Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. J Allergy Clin Immunol 97 1 pt 1 (1996) 47-52
27. Lipworth B., Tan S., Devlin M., Aiken T., Baker R., and Hendrick D. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med 104 (1998) 431-438
28. Lipworth B.J., Struthers A.D., and McDevitt D.G. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis 140 (1989) 586-592